Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS

株式のランク #17328
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
株価
$8.16
最終同期: 2025-06-26
時価総額
$234.57M
変化(1日)
0.00%
変化(1年)
-56.96%
国
US
取引 Regulus Therapeutics Inc. (RGLS)

カテゴリー

Healthcare
Regulus Therapeutics Inc.(RGLS)のP/S比率
October 2026 時点のP/S比率 TTM: 10.69
Regulus Therapeutics Inc. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 10.69 です。2022 年末時点でのP/S比率は 1.64 でした。
Regulus Therapeutics Inc. の P/S 比率の履歴(2002 ~ 2026)
各年末時点のP/S比率
年 P/S比率 変化
2026 (TTM) 10.69 107.09%
2023 5.16 214.26%
2022 1.64 -73.36%
2021 6.16 -33.92%
2020 9.33 -83.36%
2019 56.03 54.87%
2018 36.18 -4.78%
2017 38.00 -28.48%
2016 53.12 122.76%
2015 23.85 -30.11%
2014 34.12 41.52%
2013 24.11 -33.67%
2012 36.35 -50.73%
2011 73.78 -9.84%
2010 81.83 0.48%
2009 81.44 -12.87%
2008 93.48 -5.92%
2007 99.36 -13.68%
2006 115.10 -84.55%
2005 745.11 242.52%
2004 217.54 -23.37%
2003 283.88 2.98%
2002 275.67 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差 国
10.02 -6.21%
US
40.55 279.49%
US
3.96 -62.93%
AU
- -
CH
10.15 -5.05%
NL